Filing Details
- Accession Number:
- 0001209191-22-017392
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-08 21:00:22
- Reporting Period:
- 2022-03-04
- Accepted Time:
- 2022-03-08 21:00:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1478320 | Adaptive Biotechnologies Corp | ADPT | Biological Products, (No Disgnostic Substances) (2836) | 270907024 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1808905 | Mark R Adams | 1165 Eastlake Ave E Seattle WA 98109 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-03-04 | 74,135 | $0.00 | 124,968 | No | 4 | A | Direct | |
Common Stock | Disposition | 2022-03-07 | 1,244 | $12.01 | 123,724 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-03-04 | 185,338 | $0.00 | 185,338 | $12.14 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
185,338 | 2032-03-04 | No | 4 | A | Direct |
Footnotes
- This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.